SG11201807590SA - Transfected t-cells and t-cell receptors for use in immunotherapy against cancers - Google Patents

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Info

Publication number
SG11201807590SA
SG11201807590SA SG11201807590SA SG11201807590SA SG11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA SG 11201807590S A SG11201807590S A SG 11201807590SA
Authority
SG
Singapore
Prior art keywords
cells
international
present description
cell receptors
peptides
Prior art date
Application number
SG11201807590SA
Other languages
English (en)
Inventor
Dominik Maurer
Leonie Alten
Sebastian Bunk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of SG11201807590SA publication Critical patent/SG11201807590SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
SG11201807590SA 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers SG11201807590SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308970P 2016-03-16 2016-03-16
GBGB1604494.3A GB201604494D0 (en) 2016-03-16 2016-03-16 Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
PCT/EP2017/056289 WO2017158116A1 (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Publications (1)

Publication Number Publication Date
SG11201807590SA true SG11201807590SA (en) 2018-10-30

Family

ID=55952419

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807590SA SG11201807590SA (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Country Status (18)

Country Link
US (1) US10537624B2 (enExample)
EP (1) EP3430037B1 (enExample)
JP (1) JP6929867B2 (enExample)
KR (1) KR102266721B1 (enExample)
CN (1) CN108884143A (enExample)
AU (1) AU2017235069B2 (enExample)
BR (1) BR112018067989A2 (enExample)
CA (1) CA3017419A1 (enExample)
CR (1) CR20180490A (enExample)
EA (1) EA201891759A1 (enExample)
GB (1) GB201604494D0 (enExample)
MA (2) MA43328B2 (enExample)
MX (1) MX2018011223A (enExample)
PE (1) PE20190124A1 (enExample)
SG (1) SG11201807590SA (enExample)
TW (1) TWI788284B (enExample)
UA (1) UA124532C2 (enExample)
WO (1) WO2017158116A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
PL3430037T3 (pl) * 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
JP7131775B2 (ja) * 2017-02-06 2022-09-06 国立研究開発法人国立がん研究センター 新規ｔ細胞受容体
MX2020003536A (es) 2017-10-03 2020-09-14 Juno Therapeutics Inc Moleculas de union especifica a virus de papiloma humano (hpv).
BR112020016138A2 (pt) * 2018-02-11 2020-12-15 Memorial Sloan-Kettering Cancer Center Receptores de células t não restritos ao hla e usos dos mesmos
BR112020016330A8 (pt) * 2018-02-12 2023-04-18 Hutchinson Fred Cancer Res Receptores de células t específicas a ciclina a1 e usos dos mesmos
WO2019175209A1 (en) * 2018-03-14 2019-09-19 Medigene Immunotherapies Gmbh Inducible t cell receptors and uses thereof
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3773908A1 (en) * 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
AU2019344871B2 (en) * 2018-09-21 2025-04-03 Xlifesc, Ltd. High affinity T cell receptor for recognizing AFP antigen
WO2020123388A1 (en) * 2018-12-11 2020-06-18 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
CA3123352A1 (en) 2018-12-20 2020-06-25 Ava Lifescience Gmbh Method for selecting biological binding molecules
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
AU2020283500A1 (en) 2019-05-27 2022-01-27 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
CA3144054A1 (en) * 2019-06-20 2020-12-24 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
CN110357953B (zh) * 2019-07-17 2022-05-03 深圳市因诺转化医学研究院 识别人巨细胞病毒pp65抗原的TCR
WO2021022044A1 (en) * 2019-07-31 2021-02-04 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
KR20220078607A (ko) * 2019-09-12 2022-06-10 티씨알2 테라퓨틱스 인크. 융합 단백질들을 이용한 tcr 재프로그래밍을 위한 조성물 및 방법들
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
KR20230135589A (ko) 2020-12-31 2023-09-25 이매틱스 유에스 인코포레이티드 Cd8 폴리펩타이드, 조성물 및 이의 사용 방법
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
AU2014271235B2 (en) * 2008-10-01 2017-03-02 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
TW201124530A (en) 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
EP2895509B1 (en) * 2012-09-14 2019-12-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing mhc class ii-restricted mage-a3
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors

Also Published As

Publication number Publication date
AU2017235069B2 (en) 2020-05-07
EP3430037A1 (en) 2019-01-23
KR20180122430A (ko) 2018-11-12
UA124532C2 (uk) 2021-10-05
MA45309B1 (fr) 2023-01-31
WO2017158116A1 (en) 2017-09-21
MA45309A (fr) 2019-01-23
KR102266721B1 (ko) 2021-06-17
CR20180490A (es) 2019-01-10
TW201742873A (zh) 2017-12-16
GB201604494D0 (en) 2016-04-27
US10537624B2 (en) 2020-01-21
PE20190124A1 (es) 2019-01-17
JP6929867B2 (ja) 2021-09-01
MA43328B2 (fr) 2022-02-28
CN108884143A (zh) 2018-11-23
TWI788284B (zh) 2023-01-01
MA43328A1 (fr) 2019-05-31
EP3430037B1 (en) 2022-08-31
US20170312350A1 (en) 2017-11-02
CA3017419A1 (en) 2017-09-21
AU2017235069A1 (en) 2018-10-04
JP2019512242A (ja) 2019-05-16
BR112018067989A2 (pt) 2019-02-05
MX2018011223A (es) 2018-11-22
EA201891759A1 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
SG11201807590SA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201807868VA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201807300PA (en) Uterine cancer treatments
SG11201806951TA (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201806577UA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201801670YA (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
SG11201801384YA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG11201801756WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG11201809781PA (en) Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
SG11201901176XA (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
SG11201808629UA (en) Immunotherapy against melanoma and other cancers
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201808783XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201906744VA (en) Core/shell structure platform for immunotherapy
SG11201908540PA (en) Stable antibody formulation
SG11201907870VA (en) Compositions and methods for inhibition of lineage specific proteins
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201810933QA (en) Anti-c5 antibodies and uses thereof